Fanti, StefanoGoffin, KarolienHadaschik, Boris AHerrmann, KenMaurer, TobiasMacLennan, StevenOprea-Lage, Daniela E.Oyen, Wim JGRouvière, OlivierMottet, NicolasBjartell, Anders2021-02-232021-02-232021-02Fanti, S, Goffin, K, Hadaschik, B A, Herrmann, K, Maurer, T, MacLennan, S, Oprea-Lage, D E, Oyen, W JG, Rouvière, O, Mottet, N & Bjartell, A 2021, 'Consensus Statements on PSMA PET/CT Response Assessment Criteria in Prostate Cancer', European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 2, pp. 469–476. https://doi.org/10.1007/s00259-020-04934-41619-7070ORCID: 0000-0002-2691-8421ORCID: 0000-0002-5761-3786ORCID: /0000-0002-2691-8421/work/79061768https://hdl.handle.net/2164/15912Funding The one-day EAU / EANM PSMA PET/CT Response Assessment Criteria meeting received an unrestricted grant from Janssen, and no influences on the content of the meeting or on the publication. Acknowledgements The authors acknowledge John William Bean PhD (Bean Medical Writing, Halle, Belgium and funded by EAU Research Foundation) for providing medical writing services and Wim Witjes MD PhD (Scientific and Clinical Research Director EAU Research Foundation) and Emily Spieker (Management Assistant, European Association of Urology) for project management.8292517engSDG 3 - Good Health and Well-beingMonitoringOligometastatic Prostate CancerPERCISTPolymetastatic Prostate CancerProstate CancerProstate-Specific Membrane Antigen (PSMA)PSMA LigandRECISTPET/CTR Medicine (General)Radiology Nuclear Medicine and imagingR1Journal article10.1007/s00259-020-04934-4http://www.scopus.com/inward/record.url?scp=85087447530&partnerID=8YFLogxK482